BGDO | Belgian Group of Digestive Oncology

  • Plein écran
  • Ecran large
  • Ecran étroit
  • Increase font size
  • Default font size
  • Decrease font size


E-mail Print PDF

ECHO A phase II study of gemcitabine vs gemcitabine and cetuximab in patients with advanced biliary tract tumors.

The ECHO trial is a multicenter Belgian phase II study, studying the efficacy of gemcitabine and cetuximab in advanced cholangiocarcinoma cancer

Study objective :

The primary objective of this study is to evaluate the time-to-progression survival at 24 weeks.

The last patient ended trial in the summer 2010.

In meanwhile, an abstract of the ECHO trial was accepted at the ASCO-GI congress. This is the first report of a BGDO trial to an international congress. Results are exciting, as a 5.8 months PFS and 11.6 months OS was obtained, corresponding to the work hypothesis. These results will also be communicated at the next Belgian Week of Gastroenterology in February 2011.

A recently presented phase III showed superiority of the combination gemcitabine-cisplatine over gemcitabine alone. In line with these results, a new randomized phase II project will be proposed in the coming months comparing Gemcis +/- drug.